Key Highlights
- Director Keith Meister offloaded $57.19 million worth of Illumina shares in early September
- The genomics company will rejoin the S&P 500 index on September 21, months after its June 2024 removal
- Shares have surged 66.4% year-to-date, currently hovering around $218
- Second-quarter results exceeded analyst projections with revenue climbing 9.4% annually to $1.16 billion
- Analyst consensus leans toward Moderate Buy, though the average target of $197.44 suggests potential 9.5% decline
Genomics pioneer Illumina (ILMN) saw one of its directors execute a substantial stock sale last week, with Keith Meister divesting $57.19 million in company shares, according to SEC Form 4 disclosures. The multi-day transaction occurred from September 2 through September 4, involving 263,560 shares disposed of at prices between approximately $213 and $221.55.
During Friday’s trading session, shares changed hands around $218.22, declining $3.44 for the day. However, the stock recovered with nearly 1% gains in after-hours trading following the announcement of its S&P 500 reinstatement.
The divestiture was conducted through investment vehicles under Corvex Management’s control, where Meister holds the position of controlling general partner. Following these transactions, his indirect stake stands at 770,350 shares, supplemented by 6,780 shares held directly. It’s worth noting that insider transactions can stem from various motivations, ranging from strategic portfolio rebalancing to capitalizing on gains.
According to TipRanks, company insiders have collectively divested $436.7 million worth of ILMN shares during the preceding three-month period, resulting in a Very Negative insider confidence rating for the stock.
S&P 500 Index Return
The genomics company is slated to become an S&P 500 constituent once again when markets open on September 21. Alongside Illumina, Bloom Energy and Everpure will also gain admission, taking the places of Builders FirstSource, Molson Coors Beverage, and Trade Desk in the index’s quarterly restructuring.
Index membership typically generates additional buying pressure as passive funds and exchange-traded products tracking the S&P 500 rebalance their portfolios. Entry requirements mandate companies maintain a minimum market capitalization of $22.7 billion while satisfying specific profitability, trading volume, and free-float criteria.
This marks Illumina’s comeback to the prestigious index. The biotech firm was dropped from the S&P 500 during June 2024 when shares traded near $107. The current price represents a gain exceeding 100% from that level.
Financial Performance and Wall Street Sentiment
In its latest quarterly report released July 30, the company delivered earnings per share of $1.31, surpassing the Street’s consensus forecast of $1.23. Top-line results reached $1.16 billion, representing a 9.4% year-over-year increase and exceeding analyst expectations of $1.13 billion. Management established full-year 2026 EPS guidance in the range of $5.30 to $5.40.
The company has consistently outperformed earnings projections for eight consecutive quarters.
Multiple Wall Street firms elevated their price objectives following the earnings announcement. Guggenheim increased its forecast from $200 to $226, while Stifel Nicolaus adjusted upward from $155 to $225. Piper Sandler established a $225 projection, and JPMorgan boosted its estimate from $220 to $230 while maintaining an overweight recommendation.
Argus took the most bullish stance, raising its target to $235 and upgrading shares to a buy rating.
Conversely, Zacks downgraded the stock from strong buy to hold, expressing concerns about valuation following the substantial price appreciation. The aggregate consensus across MarketBeat indicates a Hold rating, with a mean price objective of $191.31, trading below current market levels.
Over the past year, ILMN has traded between $88.00 and $231.81. Institutional ownership accounts for 89.42% of outstanding shares.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
